Clinical applications of azithromycin microspheres in respiratory tract infections

International Journal of Nanomedicine

Volumn 2, Issue 4, 2007, Pages 551-559

  Blasi, Francesco ^a   Aliberti, Stefano ^a   Tarsia, Paolo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Azithromycin mierospheres; COPD exacerbations; Pneumonia

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTACID AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; DIRITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MICROSPHERE; MOXIFLOXACIN; PENICILLIN G;

ABDOMINAL PAIN; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BRONCHUS OBSTRUCTION; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; COST CONTROL; DIARRHEA; DIRECTLY OBSERVED THERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ERUPTION; DRUG TOLERABILITY; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HEADACHE; HOSPITALIZATION; HUMAN; LOOSE FECES; LOW DRUG DOSE; LOWER RESPIRATORY TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NAUSEA; PATIENT COMPLIANCE; PRESCRIPTION; REVIEW; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CAPSULES; CLINICAL TRIALS AS TOPIC; DRUG CARRIERS; HUMANS; MICROSPHERES; RESPIRATORY TRACT INFECTIONS; STAPHYLOCOCCAL INFECTIONS;

BACTERIA (MICROORGANISMS);

EID: 56049127657     PISSN: 11769114     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Allegra L, Blasi F, de Bernardi B, et al. 200 1. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. Pulm Pharmacol Ther, 14:149-55.
2. Allegra L, Blasi F, Diano PL, et al. 2005. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med, 99:742-7.
3. Amsden GW, Ballow CH, Forrest A. 1997. Comparison of the plasma, urine and blister fluid pharmacokinetics of clarithromycin and azithromycin in normal subjects. Clin Drug Invest, 13:152-61.
4. Amsden GW, Baird IM, Simon S, et al. 2003. Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest, 123:772-7.
5. Amsden GW, Gray CL. 2001. Serum and WBC pharmacokinetic of 1500 mg of azithromycin when given either as a single dose or over a 3 day period in healthy volunteers. J Antimicrob Chemother, 47:61-6.
6. Anthonisen NR, Manfreda J, Warren CP, et al. 1987. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 106:196-204.
7. Aspa J, Rajas O, Rodrigue de Castro F, et al. 2004. Drug-resistant pneumococcal pneumonia: clinical relevance and related factors. Clin Infect Dis, 38:787-98.
8. Babl FE, Pelton SI, Li Z. 2002. Experimental acute otitis media due to nontypeable Haemophilus influenzae: Comparison ofhigh and low azithromycin doses with placebo. Antimicorb Agents Chemother, 46:2194-9.
9. Blumer JL. 2005. Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin. Int J Antimicrob Agents, 26(Suppl 3): S 143-7.
10. Bohte R, van't Wout JW, Lobatto S, et al. 1995. Efficacy and safety of azithTomycin versus benzy1penicillin or erythromycin in community-acquired pneumonia. Eur J Clin Micriobiol Infect Dis, 14:182-187.
11. Bradbury F. 1993. Comparison ofazithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother, 31 (Suppl E): 153-62.
12. Cabello H, Torres A, Celis R, et al. 1997. Bacterial colonization of the distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J, 10: 1137-44.
13. Castaldo RS, Celli BR, Gomez F, et al. 2003. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Ther, 25:542-57.
14. Celli BR, MacNee W, et al. 2004. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23:932-46.
15. Chandra R, Liu P, Breen JD, et al. 2007. Clinical pharmacokinetics and gastrointestinal tolerability of a novel extended-release microsphere formulation of azithromycin. Clin Pharmacokinet, 46:247-59.
16. Claxton AJ, Cramer J, Pierce C. 2001. A systematic review of the association between dose regimens and medications compliance. Clin Ther, 23:1296-310.
17. DeAbate CA, Mathew CP, Warner JH, et al. 2000. The safety and efficacy of short course (5-day) moxifloxacin versus azithromycin in the treatment of patients with acute exacerbations of chronic bronchitis. Respir Med, 94:1029-37.
18. D'Ignazio J, Camere MA, Lewis DE, et al. 2005. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother, 49:4035-41.
19. Drehobl MA, De Salvo MC, Lewis DE, et al. 2005. Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest, 128:2230-7.
20. File TM. 2004. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis, 39:S159-64.
21. Fine MJ, Auble TE, Yealy DM, et al. 1997. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med, 336:243-50.
22. Fogarty C, Goldschmidt R, Bush K. 2000. Bacteremic pneumonia due to multidrug-resistant pneurnococci in 3 patients treated unsuccessfully with azithromycin and successfully with levolloxacin. Clin Infect Dis, 31:613-5.
23. Gay Y, Baughman W, Miller Y, et al. 2000. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis, 182:1417-24.
24. Girard D, Finegan SM, Dunne MW, et al. 2005. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother, 56:365-71.
25. Guillemot D, Carbon C, Balkau B, et al. 1998. Low dosage and long treatment duration of β-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA, 279:365-70.
26. Hand WL, Hand DL. 2001. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents, 18:419-25.
27. Handsfield HH, Dalu ZA, Martin DH, et al- 1994. Multicenter trial of single dose azithromycin vs ceftriaxone in the treatment ofunconiplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis, 21:107-11.
28. Hoepelman IM, Mollers MJ, van Schie MH, et al. 1997. A short (3-day) course of azithromycin tablets versus a 10- day course of amoxicillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents, 9:141-6.
29. Kardas P. 2002. Patient compliance with antibiotic treatment for respiratory tract infections. J Antimicrob Chemother, 49:897-903.
30. Kardas P. 2007. Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother, 59:531-6.
31. Lonks JR, Garau J, Gomez L, et al. 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis, 35:556-64.
32. Liu P, Allaudeen H, Chandra R, et al. 2007. Comparative pharmacokinetics of azithromycin in serum and white blood cells of healthy subjects receiving a single-dose extended-release regimen versus a 3-day immediate-release regimen. Antimicrob Agents Chemother, 51:103-9.
33. Mandell GL, Coleman E. 2001. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother, 45:1794-8.
34. Mandell LA, Wunderink RG, Anzueto A, et al. 2007. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis, 44:S27-72.
35. Martinez FJ. 2005. Acute exacerbation of chronic bronchitis: expanding short-course therapy. Int JAntimicrob Agents, 26 (Suppl 3):S156-63.
36. Monso E, Ruiz J, Rosell A, et al. 1995. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med, 152:1316-20.
37. Nicolau DP. 2001. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection, 29(Suppl 2):11-5.
38. Nouira S, Marghli S, Belghith M, et al. 2001. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet, 358:2020-5.
39. O'Doherty B, Muller O. 1998. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis, 17:828-33.
40. Paquette DW. 2007. Treating periodontal disease with local antimicrobials. Pract Proced Aesthet Dent, 19:233-6.
41. Patel JK, Patel MM. 2007. Stomach specific anti-helicobacter pylori therapy: preparation and evaluation of amoxicillin-loaded chitosan mucoadhesive microspheres. Curr Drug Deliv, 4:41-50.
42. Pauwels RA, Buist AS, Calverley PM, et al. 2001. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med, 163:1256-76.
43. Pijls RT, Cruysberg LP,Nuijts RM,et al. 2007. Capacity and tolerance of a new device for ocular drug delivery. Int J Pharm, 16; 341:152-61.
44. Rastogi R, Sultana Y, Ali A, Aqil M. 2006. Particulate and vesicular drug carriers in the management of tuberculosis. Curr Drug Deliv, 3:121-8.
45. Sahm DF. 2003. Resistance issues and cornmun4-acquired respiratory tract infections. Clin Cornerstone, Suppl 3:S4-11.
46. Schrag SJ, Peña C, Fernandez J, et al. 2001. Effect of short course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA, 286:49-56.
47. Schönwald S, Kuzman I, Oreskovic K, et al. 1999. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study. Infection, 27:198-202.
48. Socan M. 1998. Treatment of atypical pneumonia with azithromycin: comparison of a 5-day and a 3-day course. J Chemother, 10:64-8.
49. Stockley RA, O'Brien C, Pye A, et al. 2000. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest, 117:1638-45.
50. Takeshita E, Matsuura B, Dong M, et al. 2006. Molecular characterization and distribution of motilin family receptors in the human gastrointestinal tract. J Gastroenterol, 41:223-30.
51. Woodhead M, Blasi F, Ewig S, et al. 2005. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J, 26:1138-80.
52. Zervos M, Breen JD, Jorgensen DM, et al. 2005. Novel, single-dose microsphere formulation of azithromycin versus levofloxacin for the treatment of acute exacerbations of chronic bronchitis. Infect Dis Clin Pract, 13:1-7.